Antioxidant and renoprotective effects of paricalcitol on experimental contrast-induced nephropathy model

British Journal of Radiology

Volumn 85, Issue 1016, 2012, Pages 1038-1043

  Ari, Elif ^a   Kedrah, A E ^b   Alahdab, Y ^b   Bulut, G ^a   Eren, Z ^c   Baytekin, O ^a   Odabasi, D ^d  

^a TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

^b MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c YEDITEPE UNIVERSITY   (Turkey)

^d YUZUNCU YIL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CREATININE; INDOMETACIN; MALONALDEHYDE; MEGLUMINE DIATRIZOATE; N(G) NITROARGININE METHYL ESTER; PARICALCITOL; THIOBARBITURIC ACID REACTIVE SUBSTANCE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; KIDNEY FUNCTION; KIDNEY TUBULE NECROSIS; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; RENAL PROTECTION;

ANALYSIS OF VARIANCE; ANIMALS; ANTIOXIDANTS; BIOLOGICAL MARKERS; CONTRAST MEDIA; ERGOCALCIFEROLS; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASES; MALE; OXIDATIVE STRESS; RANDOM ALLOCATION; RATS; RATS, WISTAR; RENAL AGENTS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84864857120     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/16327485     Document Type: Article

References (27)

1. Asif A, Epstein M. Prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 2004;44:12-24. (Pubitemid 38880922)
2. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neil WW. Acute renal failure after coronary intervention; Incidence, risk factors, and relationships to mortality. Am J Med 1997;103:368-75. (Pubitemid 27506242)
3. Detrenis S, Meschi M, Musini S, Savazzi G. Lights and shadows on the pathogenesis of contrast-induced nephropathy: state of the art. Nephrol Dial Transplant 2005;20:1542-50. (Pubitemid 41418575)
4. Drüeke TB. Which vitamin D derivative to prescribe for renal patients. Curr Opin Nephrol Hypertens 2005;14:343-9.
5. Park JW, Bae EH, Kim IJ, Ma SK, Choi C, Lee J, et al. Paricalcitol attenuates cyclosporine-induced kidney injury in rats. Kidney Int 2010;77:1076-85.
6. Kuhlmann A, Haas CS, Gross ML, Reulbach U, Holzinger M, Schwarz U, et al. 1,25-dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004;286:526-33.
7. Tan X, Li Y, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 2006;17:3382-93. (Pubitemid 44865281)
8. Mizobuchi M, Morrissey J, Finch JL, Martin DR, Liapis H, Akizawa T, et al. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 2007;18:1796-806. (Pubitemid 46870316)
9. Husain K, Ferder L, Mizobuchi M, Finch J, Slatopolsky E. Combination therapy with paricalcitol and enalapril ameliorates cardiac oxidative injury in uremic rats. Am J Nephrol 2009;29:465-72.
10. Freundlich M, Quiroz Y, Zhang Z, Zhang Y, Bravo Y, Weisinger JR, et al. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 2008;74:1394-402.
11. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004;65:2003-17. (Pubitemid 38669987)
12. Rosenberger C, Griethe W, Gruber G, Weisener M, Frei U, Bachmann S, et al. Cellular responses to hypoxia after renal segmental infarction. Kidney Int 2003;64:874-86. (Pubitemid 37013823)
13. Haase VH. Hypoxia-inducible factors in the kidney. Am J Physiol Renal Physiol 2006;291:271-81.
14. Heyman S, Rosen S, Rosenberger C. Renal parenchimal hypoxia, hypoxia adaptation and the pathogenesis of radiocontrast nephropathy. Clin J Am Soc Nephrol 2008;3:288-96.
15. Agmon Y, Peleg H, Greenfield Z. Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat. J Clin Invest 1994;94:1069-75. (Pubitemid 24286448)
16. Sozmen EY, Sozmen B, Girgin FK, Delen Y, Azarsiz E, Erdener D, et al. Antioxidant enzymes and paraoxanase show a co-activity in preserving LDL from oxidation. Clin Exp Med 2001;1:195-9. (Pubitemid 34251553)
17. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-8. (Pubitemid 9194347)
18. Solez K, Kramer EC, Fox JA, Heptinstall RH. Medullary plasma flow and intravascular leukocyte accumulation in acute renal failure. Kidney Int 1974;6:24-37.
19. Rosenberger C, Heyman SN, Rosen S, Shina A, Goldfarb M, Griethe W, et al. Up-regulation of HIF in experimental acute renal failure: evidence for a protective transcriptional response to hypoxia. Kidney Int 2005;67:531-42. (Pubitemid 40139845)
20. Cetin M, Devrim E, Serin Kilicoglu S, Ergüder IB, Namuslu M, Cetin R, et al. Ionic high-osmolar contrast medium causes oxidant stress in kidney tissue: partial protective role of ascorbic acid. Ren Fail 2008;30:567-72. (Pubitemid 351874062)
21. Devrim E, Cetin M, Namuslu M, Ergüder IB, Cetin R, Durak I. Oxidant stress due to non ionic low osmolar contrast medium in rat kidney. Indian J Med Res 2009;130:433-6.
22. Toprak O, Cirit M, Tanrisev M, Yazici C, Canoz O, Sipahioglu M, et al. Preventive effect of nebivolol on contrast-induced nephropathy in rats. Nephrol Dial Transplant 2008;23:853-9. (Pubitemid 351767560)
23. Husain K, Suarez E, Isidro A, Ferder L. Effects of paricalcitol and enalapril on atherosclerotic injury in mouse aortas. Am J Nephrol 2010;32:296-304.
24. De Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010;376:1543-51.
25. Lloberas N, Torras J, Herrero-Fresneda I, Cruzado JM, Riera M, Hurtado I, et al. Postischemic renal oxidative stress induces inflammatory response through PAF and oxidized phospholipids. Prevention by antioxidant treatment. FASEB J 2002;16:908-10.
26. Durak I, Ozbek H, Karaayvaz M, Ozturk HS. Cisplatin induces acute renal failure by impairing antioxidant system in guinea pigs: effects of antioxidant supplementation on cysplatin nephrotoxicity. Drug Chem Toxicol 2002;25:1-8. (Pubitemid 34132348)
27. Kang YS, Park YG, Kim BK, Han SY, Jee YH, Han KH, et al. Angiotensin II stimulates the synthesis of vascular endothelial growth factor through the p38 mitogen activated protein kinase pathway in cultured Mouse podocytes. J Mol Endocrinol 2006;36:377-88.